CAS: 51022-71-0; (6Ar,10Ar)-1-Hydroxy-6,6-Dimethyl-3-(2-Methyloctan-2-yl)-7,8,10,10A-Tetrahydro-6Ah-Benzo[c]Chromen-9-One

专利信息

专利号:US-8258322-B2
优先权日:2008-08-28
标 题:Synthesis of hexahydrodibenzopyranones
发明人：MIKAYLO VALERIY; PARAMANANTHAM SUBAKAR; AVRUTOV ILYA; BROWN MARTYN A; LI ZEMIN; LAZAROWYCH NATALIE
权利人:MIKAYLO VALERIY; PARAMANANTHAM SUBAKAR; AVRUTOV ILYA; BROWN MARTYN A; LI ZEMIN; LAZAROWYCH NATALIE; WATSON LAB INC
摘要:An improved process is provided for the synthesis of hexahydrodibenzo[b,d]pyran-9-ones, such as nabilone.

专利号:US-12234203-B2
优先权日:2020-03-12
标 题:Process for the synthesis of cannabidiol and intermediates thereof
发明人：ANAND RADHIKA; SHARMA SUMIT; SINGH CHAM PANKAJ; GANNEDI VEERANJANEYULU; KUMAR MUKESH; PRATAP SINGH VARUN; PRAKASH RAHUL VISHAV; ASREY VISHWAKARMA RAM; PAL SINGH PARVINDER
权利人:COUNCIL OF SCIENT AND INDUSTRIAL RESEARCH AN INDIAN REGISTERED BODY INCORPORATED UNDER THE REGN OF T; COUNCIL OF SCIENT AND INDUSTRIAL RESEARCH AN INDIAN REGISTERED BODY INCORPORATED UNDER THE REGN OF S
摘要:The present invention relates to process for the preparation of cannabidiol (A) from the coupling of (D) and (E) through the intermediates (C) and (D) starting from compound (B). The invention further relates to the novel compounds (B), (C), (D) and (E) and reagents used in this process. More specifically, this invention provides the manufacturing of Cannabidiol (A) in milligram to gram or kilogram scale.

专利号:US-2008214827-A1
优先权日:2004-02-03
标 题:Synthesis of Cyanoimino-Benzoimidazoles
发明人：GOEHRING R RICHARD; WHITEHEAD JOHN; SHAO BIN
权利人:EURO CELTIQUE SA
摘要:Disclosed in certain embodiments is a process for synthesizing a compound of formula (V) and salts thereof.

专利号:US-9861609-B2
优先权日:2013-02-28
标题:Chemical engineering processes and apparatus for the synthesis of compounds
发明人：WINNICKI ROBERT; DONSKY MARC; SUN MINGYANG; PEET RICHARD
权利人:FULL SPECTRUM LABORATORIES LTD
摘要:The present invention provides methods for producing cannabinoids and cannabinoid analogs as well as a system for producing these compounds. The inventive method is directed to contacting a compound according to Formula I or Formula II with a cannabinoid synthase. n nAlso described is a system for producing cannabinoids and cannabinoid analogs by contacting a THCA synthase with a cannabinoid precursor and modifying at least one property of the reaction mixture to influence the quantity formed of a first cannabinoid relative to the quantity formed of a second cannabinoid.

专利号:US-12194020-B2
优先权日:2017-12-22
标 题:Reversing baldness through cannabinoid receptor activation
发明人：POSTREL RICHARD
权利人:POSTREL RICHARD
摘要:This invention reverses male pattern baldness by shocking dormant hair follicles out of their androgen induced hibernation phase back to the active hair-growing anagenic phase. The invention integrates two functions: 1) It blocks synthesis of compounds holding the follicles in the telogenic/hibernating phase and 2) It stimulates synthesis of compounds animating the hair-growing/anagenic phase in the follicular activity cycle. One preferred embodiment comprises an enzyme inhibitor blocking the conversion of testosterone to dihydrotestosterone (DHT), a flavonoid simultaneously increasing synthesis of prostaglandins alternative to prostaglandin D2, and a selected cannabinoid compound stimulating restore the hair follicle to its normal growth cycle. This novel trimodal therapy restores the hair follicles to their normal cycling processes and maintains these restorative properties so long as this rebalance in maintained.

专利号:US-2022118123-A1
优先权日:2019-02-22
标 题 :Combination of ar antagonists and targeted thorium conjugates
发明人：HAMMER STEFANIE; HAGEMANN URS BEAT; HAENDLER BERNARD; LEJEUNE PASCALE; ZITZMANN-KOLBE SABINE; SCHATZ CHRISTOPH; KARLSSON JENNY
权利人:BAYER AG; BAYER AS
摘要:The present invention covers combinations of at least two components, component A and component B, comprising component A being PSMA-TTC, and component B being an antiandrogen selected form AR antagonists such as from cyproterone acetate, bicalutamide, flutamide, nilutamide, enzalutamide, apalutamide, darolutamide or keto-darolutamide, or an AR degrader such as ARV-110, or an ARN-terminal domain binder such as EPI-506, or an antisense oligonucleotide that reduces AR expression such as EZN-4176 or AZD-5312, or an androgen synthesis inhibitor such as abiraterone, particularly abiraterone acetate, seviteronel, galeterone, orteronel or ketoconazole, or a dual AR antagonist and androgen synthesis inhibitor such as ODM-204. Another aspect of the present invention covers the use of such combinations as described herein for the preparation of a medicament for the treatment or prophylaxis of a disease, particularly for the treatment of a hyper-proliferative disease.